Thank you for sharing!

Your article was successfully shared with the contacts you provided.

A recent decision from the Delaware District Court held that the composition of matter patent for the drug Baraclude was invalid as obvious. This opinion has drawn immediate attention because it is the first time that a lead compound obviousness challenge has succeeded in a district court since KSR v. Teleflex issued. What this means for inside counsel depends on which side of the aisle you are on, but regardless this decision may provide the beachhead for obviousness attacks where none existed before. For generic pharmaceutical companies, the ruling may affect pre-filing decisions, such as which patents to attack listed with the Orange Book and concomitant certifications, may take on a sizeable shift, and change the landscape for at-risk launches.  Patent prosecutors should also heed the court’s decision when drafting claims.

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2017 ALM Media Properties, LLC. All Rights Reserved.